Alterations of glycosaminoglycans in human liver and kidney tumors.

K. Lapis, I. Kavalsky, A. Jeney, G. Pogány, G. Molnár, D. Répássy, A. Szécsény, S. Karácsonyi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Glycosaminoglycans were investigated in surgically removed human liver and kidney tumours by applying biochemical methods. Four liver adenoma, 6 focal nodular hyperplasia and 9 primary hepatocellular carcinoma samples were compared with normal liver from autopsy cases and also with liver tissue adjacent to PHC. The studies on kidney included 14 renal cell carcinoma and 4 wilms' tumour samples. Three findings emerged from the quantitative and qualitative characterization of the tumours with epithelial origin. 1) The rise in the amount of total GAG was not limited to the malignant lesion. Similar increase was observed in benign liver tumours and also in the tissue adjacent to liver or kidney malignant tumours. 2) The dominant type of the GAG subclasses varies with the histology of the tumours. In benign liver tumours dermatan sulfate, in PHC and renal cell carcinoma chondroitin sulfate, but in Wilms' tumour hyaluronate was the prominent GAG subclass. 3) In all tumour-affected tissues dermatan and chondroitin sulfates had lower degree of sulfation. However, in the histologically different tumours various disaccharides showed reduced level of sulfation. The GAG alteration in renal cell carcinoma was compared with the prognostic factors of each individual case. This analysis showed a good correlation between HS/CS ratio and the prognostic factors of the kidney tumour cases.

Original languageEnglish
Pages (from-to)155-165
Number of pages11
JournalTokai Journal of Experimental and Clinical Medicine
Volume15
Issue number2-3
Publication statusPublished - May 1990

Fingerprint

Glycosaminoglycans
Kidney
Liver
Neoplasms
Renal Cell Carcinoma
Dermatan Sulfate
Chondroitin Sulfates
Focal Nodular Hyperplasia
Wilms Tumor
Disaccharides
Adenoma
Hepatocellular Carcinoma
Autopsy
Histology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lapis, K., Kavalsky, I., Jeney, A., Pogány, G., Molnár, G., Répássy, D., ... Karácsonyi, S. (1990). Alterations of glycosaminoglycans in human liver and kidney tumors. Tokai Journal of Experimental and Clinical Medicine, 15(2-3), 155-165.

Alterations of glycosaminoglycans in human liver and kidney tumors. / Lapis, K.; Kavalsky, I.; Jeney, A.; Pogány, G.; Molnár, G.; Répássy, D.; Szécsény, A.; Karácsonyi, S.

In: Tokai Journal of Experimental and Clinical Medicine, Vol. 15, No. 2-3, 05.1990, p. 155-165.

Research output: Contribution to journalArticle

Lapis, K, Kavalsky, I, Jeney, A, Pogány, G, Molnár, G, Répássy, D, Szécsény, A & Karácsonyi, S 1990, 'Alterations of glycosaminoglycans in human liver and kidney tumors.', Tokai Journal of Experimental and Clinical Medicine, vol. 15, no. 2-3, pp. 155-165.
Lapis, K. ; Kavalsky, I. ; Jeney, A. ; Pogány, G. ; Molnár, G. ; Répássy, D. ; Szécsény, A. ; Karácsonyi, S. / Alterations of glycosaminoglycans in human liver and kidney tumors. In: Tokai Journal of Experimental and Clinical Medicine. 1990 ; Vol. 15, No. 2-3. pp. 155-165.
@article{119ddb31a17247da8a90b29832137435,
title = "Alterations of glycosaminoglycans in human liver and kidney tumors.",
abstract = "Glycosaminoglycans were investigated in surgically removed human liver and kidney tumours by applying biochemical methods. Four liver adenoma, 6 focal nodular hyperplasia and 9 primary hepatocellular carcinoma samples were compared with normal liver from autopsy cases and also with liver tissue adjacent to PHC. The studies on kidney included 14 renal cell carcinoma and 4 wilms' tumour samples. Three findings emerged from the quantitative and qualitative characterization of the tumours with epithelial origin. 1) The rise in the amount of total GAG was not limited to the malignant lesion. Similar increase was observed in benign liver tumours and also in the tissue adjacent to liver or kidney malignant tumours. 2) The dominant type of the GAG subclasses varies with the histology of the tumours. In benign liver tumours dermatan sulfate, in PHC and renal cell carcinoma chondroitin sulfate, but in Wilms' tumour hyaluronate was the prominent GAG subclass. 3) In all tumour-affected tissues dermatan and chondroitin sulfates had lower degree of sulfation. However, in the histologically different tumours various disaccharides showed reduced level of sulfation. The GAG alteration in renal cell carcinoma was compared with the prognostic factors of each individual case. This analysis showed a good correlation between HS/CS ratio and the prognostic factors of the kidney tumour cases.",
author = "K. Lapis and I. Kavalsky and A. Jeney and G. Pog{\'a}ny and G. Moln{\'a}r and D. R{\'e}p{\'a}ssy and A. Sz{\'e}cs{\'e}ny and S. Kar{\'a}csonyi",
year = "1990",
month = "5",
language = "English",
volume = "15",
pages = "155--165",
journal = "Tokai Journal of Experimental and Clinical Medicine",
issn = "0385-0005",
publisher = "Tokai Medical Association",
number = "2-3",

}

TY - JOUR

T1 - Alterations of glycosaminoglycans in human liver and kidney tumors.

AU - Lapis, K.

AU - Kavalsky, I.

AU - Jeney, A.

AU - Pogány, G.

AU - Molnár, G.

AU - Répássy, D.

AU - Szécsény, A.

AU - Karácsonyi, S.

PY - 1990/5

Y1 - 1990/5

N2 - Glycosaminoglycans were investigated in surgically removed human liver and kidney tumours by applying biochemical methods. Four liver adenoma, 6 focal nodular hyperplasia and 9 primary hepatocellular carcinoma samples were compared with normal liver from autopsy cases and also with liver tissue adjacent to PHC. The studies on kidney included 14 renal cell carcinoma and 4 wilms' tumour samples. Three findings emerged from the quantitative and qualitative characterization of the tumours with epithelial origin. 1) The rise in the amount of total GAG was not limited to the malignant lesion. Similar increase was observed in benign liver tumours and also in the tissue adjacent to liver or kidney malignant tumours. 2) The dominant type of the GAG subclasses varies with the histology of the tumours. In benign liver tumours dermatan sulfate, in PHC and renal cell carcinoma chondroitin sulfate, but in Wilms' tumour hyaluronate was the prominent GAG subclass. 3) In all tumour-affected tissues dermatan and chondroitin sulfates had lower degree of sulfation. However, in the histologically different tumours various disaccharides showed reduced level of sulfation. The GAG alteration in renal cell carcinoma was compared with the prognostic factors of each individual case. This analysis showed a good correlation between HS/CS ratio and the prognostic factors of the kidney tumour cases.

AB - Glycosaminoglycans were investigated in surgically removed human liver and kidney tumours by applying biochemical methods. Four liver adenoma, 6 focal nodular hyperplasia and 9 primary hepatocellular carcinoma samples were compared with normal liver from autopsy cases and also with liver tissue adjacent to PHC. The studies on kidney included 14 renal cell carcinoma and 4 wilms' tumour samples. Three findings emerged from the quantitative and qualitative characterization of the tumours with epithelial origin. 1) The rise in the amount of total GAG was not limited to the malignant lesion. Similar increase was observed in benign liver tumours and also in the tissue adjacent to liver or kidney malignant tumours. 2) The dominant type of the GAG subclasses varies with the histology of the tumours. In benign liver tumours dermatan sulfate, in PHC and renal cell carcinoma chondroitin sulfate, but in Wilms' tumour hyaluronate was the prominent GAG subclass. 3) In all tumour-affected tissues dermatan and chondroitin sulfates had lower degree of sulfation. However, in the histologically different tumours various disaccharides showed reduced level of sulfation. The GAG alteration in renal cell carcinoma was compared with the prognostic factors of each individual case. This analysis showed a good correlation between HS/CS ratio and the prognostic factors of the kidney tumour cases.

UR - http://www.scopus.com/inward/record.url?scp=0025431165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025431165&partnerID=8YFLogxK

M3 - Article

C2 - 2130524

AN - SCOPUS:0025431165

VL - 15

SP - 155

EP - 165

JO - Tokai Journal of Experimental and Clinical Medicine

JF - Tokai Journal of Experimental and Clinical Medicine

SN - 0385-0005

IS - 2-3

ER -